OnKure Therapeutics is a clinical-stage precision-medicine company with no marketed products or revenue, so its valuation is driven almost entirely by analyst judgment about its drug pipeline rather than current financial results. Four verifiable analyst price targets were reviewed to build the central target: Leerink Partners set an Outperform rating with an $11 target (March 30, 2026), Oppenheimer's Matthew Biegler reiterated a Buy with a $14 target (August 14, 2026), LifeSci Capital's Sam Slutsky maintained a Buy with a $16 target (August 6, 2026), and H.C. Wainwright's Robert Burns reiterated a Buy with a $21 target (July 20, 2026). JonesTrading carries a Hold rating but does not publish a price target.
The mean of those four targets is $15.50, with a range of $11 to $21. That unusually wide spread signals genuine disagreement: the bulls are underwriting the next-generation PI3Kα (phosphoinositide 3-kinase alpha) programs, while more cautious analysts discount dilution and clinical-execution risk. Notably, every target has been cut from earlier, higher levels — Oppenheimer from $30, H.C. Wainwright from $27, and Leerink from $29 — as the company pivoted its strategy and raised capital.
OKUR last traded around $2.60, giving the company a market capitalization near $105 million. Because the stock trades below its book value per share of roughly $4.25 and carries about $4.36 in cash per share, the shares are effectively pricing in substantial uncertainty about the pipeline. Reaching $15.50 would require a move of approximately 497% — a very large percentage advance for a pre-revenue biotech.
The theoretical path involves de-risking the company's next-generation PI3Kα pan-mutant selective inhibitors, OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND (investigational new drug) submissions planned for the first half of 2027. Any positive clinical data or a partnership could force a re-rating, but such outcomes are inherently uncertain and not guaranteed.
The clearest support is financial: the company held roughly $176 million in cash at its most recent report, funded in part by a $150 million private placement led by Access Biotechnology. With cash per share above the current stock price and minimal debt, the balance sheet reduces near-term dilution overhang relative to many peers. The strategic pivot toward broader PI3Kα pan-mutant inhibitors has been framed by management as addressing a larger patient opportunity than the original OKI-219 H1047R-specific program. Four of the analysts publishing targets carry Buy or Outperform ratings, suggesting the sell-side broadly sees the risk-reward as skewed favorably despite the low share price.
The principal obstacle is that OnKure generates no revenue and posted a trailing net loss near $59 million, so it depends on continued clinical and financing execution. The repeated downward revisions to price targets reflect concerns about share dilution, the shift in strategic focus, and the long timeline before potential commercialization. The stock also trades below its 50-day moving average (about $3.02) and its 200-day moving average (about $3.62), indicating weak technical momentum. A clinical setback, a regulatory delay, or further dilution could keep the shares well below even the lowest analyst target.
The shares sit in the lower portion of a 52-week range of $2.01 to $5.38, near the lower bound. The $2.00 area has acted as a psychological and structural floor over the past year, while the 50-day and 200-day moving averages near $3.00 and $3.62 form overhead supply. A sustained recovery would need to clear those levels before the stock could begin a longer-term move toward analyst targets, which themselves sit far above any recent trading zone.
These analyst price targets generally reflect a roughly 12-month research horizon, though individual analysts do not publish identical timelines. Key upcoming items include quarterly earnings, guidance on cash runway, and updates on the OKI-345 and OKI-355 IND submissions expected in the first half of 2027. Investors should also watch for any clinical data readouts, partnering announcements, analyst target revisions, and changes in the company's financing plans, since any of these can materially shift sentiment for a pre-revenue biotech.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive name like OKUR, such tools can help traders identify shifting trends and monitor positions more efficiently than manual chart review. Explore the signals to see how the model is reading this ticker and the broader market.
The $15.50 central target is the average of four verified analyst price targets ranging from $11 to $21, and it sits roughly 497% above the current price near $2.60 — a very large required move. Support comes from a strong cash position, cash per share above the stock price, and a pipeline refocused on broader PI3Kα programs. The principal obstacles are the absence of revenue, ongoing cash burn, dilution, and a history of downward target revisions. Given the wide analyst spread and the stock's position below its moving averages, reaching $15.50 depends on clinical and regulatory milestones that are far from assured. Investors should monitor data readouts, IND filings, financing activity, and analyst revisions rather than treat the target as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, OKUR has been loosely correlated with ELDN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if OKUR jumps, then ELDN could also see price increases.
| Ticker / NAME | Correlation To OKUR | 1D Price Change % | ||
|---|---|---|---|---|
| OKUR | 100% | +6.11% | ||
| ELDN - OKUR | 34% Loosely correlated | -3.83% | ||
| MGX - OKUR | 32% Poorly correlated | -3.01% | ||
| SGMT - OKUR | 32% Poorly correlated | +0.55% | ||
| CABA - OKUR | 32% Poorly correlated | -3.33% | ||
| IDYA - OKUR | 32% Poorly correlated | -0.87% | ||
More | ||||